The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Contraindicated Use of Cisapride: Impact of Food and Drug Administration Regulatory Action
Abstract
CONTEXT: Cisapride, a gastrointestinal tract promotility agent, can cause life-threatening cardiac arrhythmias in patients susceptible either because of concurrent use of medications that interfere with cisapride metabolism or prolong the QT interval or because of the presence of other diseases that predispose to such arrhythmias. In June 1998, the US Food and Drug Administration (FDA) determined that use of cisapride was contraindicated in such patients and informed practitioners through additions to the boxed warning in the label and a "Dear Health Care Professional" letter sent by the drug's manufacturer. OBJECTIVE: To evaluate the impact of the FDA's 1998 regulatory action regarding contraindicated use of cisapride. DESIGN AND SETTING: Analysis of data for the 1-year periods before (July 1997-June 1998) and after (July 1998-June 1999) the regulatory action from the population-based, pharmacoepidemiology research databases of 2 managed care organizations (sites A and B) and a state Medicaid program (site C). PARTICIPANTS: Patients with at least 180 days of prior enrollment in 1 of the 3 sites who were prescribed cisapride at least once in the period before (n = 24 840) or after (n = 22 459) regulatory action. Patients could be included in both cohorts. MAIN OUTCOME MEASURES: Proportion of cisapride users in each period for whom cisapride use was contraindicated by the product label, based on computerized patient medical encounter records. RESULTS: In the year prior to regulatory action, cisapride use was contraindicated for 26%, 30%, and 60% of users in study sites A, B, and C, respectively. In the year after regulatory action, use was contraindicated for 24%, 28%, and 58% of users, a reduction in contraindicated use of approximately 2 per 100 cisapride users at each site. When the analysis was restricted to new users of cisapride after regulatory action, only minor reductions in contraindicated use were found. CONCLUSION: The FDA's 1998 regulatory action regarding cisapride use had no material effect on contraindicated cisapride use. More effective ways to communicate new information about drug safety are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cisapride and Fatal Arrhythmia
Wysowski, D. K., & Bacsanyi, J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607253350416 · Cited by 331
Self-citationUSE OF MEDICAID DATA FOR PHARMACOEPIDEMIOLOGY
RAY, W. A., & GRIFFIN, M. R. (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115198 · Cited by 315
Self-citationInternational Classification of Diseases, Ninth Revision, Clinical Modification
National Cancer Institute (2020) · Definitions · doi:10.32388/ggn38l · Cited by 294
The influence of cisapride and clarithromycin on QT intervals in healthy volunteers
van Haarst, A. D., Klooster, G. A. E. V. '., van Gerven, J., Schoemaker, R. C., van Oene, J. C., Burggraaf, J., Coene, M. C., & Cohen, A. F. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90137-0 · Cited by 147
Evaluating Drugs after Their Approval for Clinical Use
Ray, W. A., Griffin, M. R., & Avorn, J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292710 · Cited by 131
Self-citationPhysicians' Current Procedural Terminology.
Cb, J. (1973) · PubMed · Cited by 126
Torsade De Pointes Induced by Cisapride/Clarithromycin Interaction
Piquette, R. K. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18107 · Cited by 103
Cisapride‐Induced Torsades de Pointes
Vitola, J. V., Vukanovic, J., & Roden, D. M. (1998) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.1998.tb00888.x · Cited by 84
Torsades de pointes in two chronic renal failure patients treated with Cisapride and Clarithromycin
Sekkarie, M. A. (1997) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(97)90291-2 · Cited by 70
Centers for Education and Research in Therapeutics
Woosley, R. L. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.24 · Cited by 38
Cited by
What Clinicians Should Know About the QT Interval
Al-Khatib, S. M., LaPointe, N. M. A., Kramer, J. M., & Califf, R. M. (2003) · JAMA · doi:10.1001/jama.289.16.2120 · Cited by 667
Safety of Patients Isolated for Infection Control
Stelfox, H. T. (2003) · JAMA · doi:10.1001/jama.290.14.1899 · Cited by 566
Liang, P., Lan, F., Lee, A. S., Gong, T., Sanchez-Freire, V., Wang, Y., Diecke, S., Sallam, K., Knowles, J. W., Wang, P. J., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.001883 · Cited by 537
Viskin, S., Rosovski, U., Sands, A. J., Chen, E., Kistler, P. M., Kalman, J. M., Rodriguez Chavez, L., Iturralde Torres, P., Cruz F, F. E. S., Centurión, O. A., et al. (2005) · Heart Rhythm · doi:10.1016/j.hrthm.2005.02.011 · Cited by 409
Towards understanding the de-adoption of low-value clinical practices: a scoping review
Niven, D. J., Mrklas, K. J., Holodinsky, J. K., Straus, S. E., Hemmelgarn, B. R., Jeffs, L. P., & Stelfox, H. T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0488-z · Cited by 369
Metadata
- Authors
- Smalley, W., Shatin, D., Wysowski, D. K., Gurwitz, J., Andrade, S. E., Goodman, M., Chan, K. A., Platt, R., Schech, S. D., & Ray, W. A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2000-12-20
- Volume
- 284
- Issue
- 23
- Pages
- 3036
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2102816291
- Cited by
- 255
- References
- 10
- FWCI
- 27.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Contraindicated Use of Cisapride: Impact of Food and Drug Administration Regulatory Action. https://app.cochat.ai/papers/10.1001/jama.284.23.3036
- The paper
- Smalley, W., Shatin, D., Wysowski, D. K., Gurwitz, J., Andrade, S. E., Goodman, M., Chan, K. A., Platt, R., Schech, S. D., & Ray, W. A. (2000). Contraindicated Use of Cisapride: Impact of Food and Drug Administration Regulatory Action. JAMA. https://doi.org/10.1001/jama.284.23.3036
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.